- Home
- TNYA
as 07-26-2024 4:00pm EST
Tenaya Therapeutics Inc is a preclinical stage biotechnology company focused on discovering, developing, and delivering curative therapies that address the underlying drivers of heart disease. It is advancing product candidates from three product platforms: gene therapy, cellular regeneration, and precision medicine.
| Founded: | 2016 | Country: | United States |
| Employees: | N/A | City: | SOUTH SAN FRANCISCO |
| Market Cap: | 356.5M | IPO Year: | 2021 |
| Target Price: | $15.00 | AVG Volume (30 days): | 406.7K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.64 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.66 - $7.01 | Next Earning Date: | 08-07-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | 359.94% |
Stock Insider Trading Activity of Tenaya Therapeutics Inc. (TNYA)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Hoey Timothy | TNYA | Chief Scientific Officer | Mar 5 '24 | Sell | $7.00 | 3,300 | $23,100.99 | 245,346 | SEC Form 4 |
| Hoey Timothy | TNYA | Chief Scientific Officer | Feb 20 '24 | Sell | $5.31 | 6,369 | $33,813.02 | 236,346 | SEC Form 4 |
| Hoey Timothy | TNYA | Chief Scientific Officer | Feb 20 '24 | Sell | $6.17 | 200 | $1,233.00 | 236,146 | SEC Form 4 |
| PATTERSON LEONE D | TNYA | Chief Fin. and Bus. Officer | Feb 16 '24 | Sell | $5.86 | 5,201 | $30,477.86 | 60,755 | SEC Form 4 |
| Ali Faraz | TNYA | Chief Executive Officer | Feb 16 '24 | Sell | $5.86 | 6,358 | $37,257.88 | 113,079 | SEC Form 4 |
| Tingley Whittemore | TNYA | Chief Medical Officer | Feb 16 '24 | Sell | $5.86 | 6,500 | $38,090.00 | 73,534 | SEC Form 4 |
| Hoey Timothy | TNYA | Chief Scientific Officer | Feb 16 '24 | Sell | $5.86 | 4,681 | $27,430.66 | 242,715 | SEC Form 4 |
| COLUMN GROUP III GP, LP | TNYA | 10% Owner | Feb 12 '24 | Buy | $4.50 | 2,222,222 | $9,999,999.00 | 13,599,275 | SEC Form 4 |
| GOEDDEL DAVID V | TNYA | Director10% Owner | Feb 12 '24 | Buy | $4.50 | 2,222,222 | $9,999,999.00 | 13,599,275 | SEC Form 4 |
Latest Tenaya Therapeutics Inc. News
TNYA Breaking Stock News: Dive into TNYA Ticker-Specific Updates for Smart Investing
GlobeNewswire
a month ago
Tenaya Therapeutics Announces Research Leadership Updates
GlobeNewswire
a month ago
Tenaya Therapeutics to Participate at the TD Cowen Genetic Medicines & RNA Summit
MT Newswires
2 months ago
William Blair Starts Tenaya Therapeutics With Outperform Rating
Motley Fool
2 months ago
BigBear.ai Stock: Buy, Sell, or Hold?
AFP
2 months ago
Indonesia's first Olympic gymnast encourages others to 'dream higher'
Motley Fool
2 months ago
Where Will CrowdStrike Stock Be in 1 Year?
GuruFocus.com
2 months ago
Warren Buffett's Strategic Acquisition in Occidental Petroleum Corp
GuruFocus.com
2 months ago
Insider Sale: EVP, CEO of Patient Direct, Perry Bernocchi, Sells Shares of Owens & Minor ...
Compare TNYA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "TNYA Tenaya Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.